rs11859077 - VN2R10P - ADAMTS18
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. - Nature genetics (2022) · Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Hinds DA, Gelernter J, Levey DF, Polimanti R, Stein MB, Van Someren EJW, Smit AB, Posthuma D · PubMed 35835914
Insomnia is a heritable, highly prevalent sleep disorder for which no sufficient treatment currently exists. Previous genome-wide association studies with up to 1.3 million subjects identified over 200 associated loci. This extreme polygenicity suggested that many more loci remain to be discovered. The current study almost doubled the sample size to 593,724 cases and 1,771,286 controls, thereby increasing statistical power, and identified 554 risk loci (including 364 novel loci). To capitalize on this large number of loci, we propose a novel strategy to prioritize genes using external biological resources and functional interactions between genes across risk loci. Of all 3,898 genes naively implicated from the risk loci, we prioritize 289 and find brain-tissue expression spec
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Discuss genetic insomnia predisposition with provider Moderate
Large GWAS signal warrants clinical assessment for underlying sleep disorder and appropriate management
Raise sleep difficulties, daytime consequences, and family history of sleep issues
Lifestyle
-
Maintain consistent sleep-wake schedule Moderate
Regular circadian rhythm supports sleep homeostasis and may reduce expression of genetic predisposition
Set consistent bedtime and wake time daily, including weekends, within 30-minute window
Screening
-
Screen for insomnia and sleep quality Moderate
rs11859077 T allele is associated with significantly elevated insomnia risk (GWAS p=9.0e-10, n=2365010)
Assess sleep onset latency, duration, and daytime impairment at baseline and annually